Nextcure Inc (NXTC)
$1.31
Performance
- $1.29$1.34$1.31
1.15%
Downside
Day's Volatility :3.37%
Upside
2.24%
- $0.98$2.57$1.31
25.19%
Downside
52 Weeks Volatility :61.87%
Upside
49.03%
Returns
| Period | Nextcure Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -12.74% | 0.0% |
6 Months | -42.92% | 0.0% |
1 Year | 3.79% | 0.0% |
3 Years | -82.53% | -21.1% |
Highlights
Market Capitalization | 38.6M |
Book Value | $3.05 |
Earnings Per Share (EPS) | -2.17 |
Wall Street Target Price | 5.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -31.09% |
Return On Equity TTM | -54.75% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -54.2M |
EBITDA | -60.4M |
Diluted Eps TTM | -2.17 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.87 |
EPS Estimate Next Year | -1.56 |
EPS Estimate Current Quarter | -0.38 |
EPS Estimate Next Quarter | -0.37 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 281.68%
Technicals Summary
Sell
Neutral
Buy
Nextcure Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Nextcure Inc | -8.05% | -42.92% | 3.79% | -82.53% | -95.58% |
 Regeneron Pharmaceuticals, Inc. | -10.06% | 10.55% | 30.05% | 89.27% | 274.48% |
 Novo Nordisk A/s | -12.62% | -6.24% | 35.65% | 145.66% | 372.59% |
 Alnylam Pharmaceuticals, Inc. | 8.37% | 82.34% | 59.06% | 41.03% | 258.58% |
 Vertex Pharmaceuticals Incorporated | -2.23% | 13.76% | 34.75% | 162.16% | 172.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Nextcure Inc | NA | NA | NA | -1.87 | -0.55 | -0.31 | NA | 3.05 |
Regeneron Pharmaceuticals, Inc. | 27.85 | 27.85 | 1.43 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.39 | 40.39 | 1.82 | 3.45 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.56 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Nextcure Inc | Buy | $38.6M | -95.58% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $115.9B | 274.48% | 27.85 | 32.04% |
Novo Nordisk A/s | Buy | $531.4B | 372.59% | 40.39 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $35.3B | 258.58% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.0B | 172.77% | 32.84 | -4.74% |
Insights on Nextcure Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.1% return, outperforming this stock by 55.3%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 42.7% return, outperforming this stock by 124.6%
Institutional Holdings
Logos Global Management LP
17.87%Sofinnova Ventures
9.55%Affinity Asset Advisors, LLC
6.03%Orbimed Advisors, LLC
4.08%Vanguard Group Inc
3.53%BlackRock Inc
2.72%
Company Information
nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col
Organization | Nextcure Inc |
Employees | 82 |
CEO | Mr. Michael S. Richman MSBA |
Industry | Biotechnology |
Discover More
Spdr S&p Global Dividend Etf
$1.31
-1.5%
Flotek Industries Inc
$1.31
-1.5%
Bank Of N.t. Butterfield & Son Limited
$1.31
-1.5%
Trio Petroleum Corp
$1.31
-1.5%
Ft Cboe Vest Us Eqy D Bu-may
$1.31
-1.5%
Cherry Hill Mortgage Investment Corp
$1.31
-1.5%
Invesco Bulletshares 2025 Hi
$1.31
-1.5%
Invesco Large Cap Value Etf
$1.31
-1.5%
Ft Cboe Vest Us Equity Moderate Buffer Etf - Apr
$1.31
-1.5%